Multinational, multicentre, randomised, open-label study evaluating the impact of a 91-day extended regimen combined oral contraceptive, compared with two 28-day traditional combined oral contraceptives, on haemostatic parameters in healthy women

Rossella E. Nappi, Anna Maria Paoletti, Annibale Volpe, Luca Chiovato, Brandon Howard, Herman Weiss, Nancy Ricciotti

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives To evaluate the impact of a 91-day extended regimen combined oral contraceptive (150 μg levonorgestrel [LNG]/30 μg ethinylestradiol [EE] for 84 days, followed by 10 μg EE for seven days [Treatment 1]) compared with two traditional 21/7 regimens (21 days 150 μg LNG/30 μg EE [Treatment 2] or 150 μg desogestrel [DSG]/30 μg EE [Treatment 3], both with seven days' hormone free), on several coagulation factors and thrombin formation markers. Methods Randomised, open-label, parallel-group comparative study involving healthy women (18-40 years). The primary endpoint was change from baseline in prothrombin fragment 1 + 2 (F1 + 2) levels over six months. Results A total of 187 subjects were included in the primary analysis. In all groups, mean F1 + 2 values were elevated after six months of treatment. Changes were comparable between Treatments 1 and 2 (least squares mean change: 170 pmol/L and 158 pmol/L, respectively) but noticeably larger after Treatment 3 (least squares mean change: 592 pmol/L). The haemostatic effects of Treatment 1 were comparable to those of Treatment 2 and noninferior to those of Treatment 3 (lower limit of 95% confidence interval [- 18.3 pmol/L] > - 130 pmol/L). Conclusions The LNG/EE regimens had similar effects on F1 + 2. Noninferiority was demonstrated between extended regimen LNG/EE and DSG/EE.

Original languageEnglish
Pages (from-to)285-294
Number of pages10
JournalEuropean Journal of Contraception and Reproductive Health Care
Volume19
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Contraceptives, Oral, Combined
Hemostatics
Ethinyl Estradiol
Levonorgestrel
Desogestrel
Therapeutics
Least-Squares Analysis
Blood Coagulation Factors
Thrombin
Hormones
Confidence Intervals

Keywords

  • Coagulation
  • Combined oral contraceptives
  • Desogestrel
  • Haemostatic
  • Levonorgestrel

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Pharmacology (medical)
  • Reproductive Medicine
  • Medicine(all)

Cite this

@article{eed85d3ca2394fc7a190f63c5bd1d818,
title = "Multinational, multicentre, randomised, open-label study evaluating the impact of a 91-day extended regimen combined oral contraceptive, compared with two 28-day traditional combined oral contraceptives, on haemostatic parameters in healthy women",
abstract = "Objectives To evaluate the impact of a 91-day extended regimen combined oral contraceptive (150 μg levonorgestrel [LNG]/30 μg ethinylestradiol [EE] for 84 days, followed by 10 μg EE for seven days [Treatment 1]) compared with two traditional 21/7 regimens (21 days 150 μg LNG/30 μg EE [Treatment 2] or 150 μg desogestrel [DSG]/30 μg EE [Treatment 3], both with seven days' hormone free), on several coagulation factors and thrombin formation markers. Methods Randomised, open-label, parallel-group comparative study involving healthy women (18-40 years). The primary endpoint was change from baseline in prothrombin fragment 1 + 2 (F1 + 2) levels over six months. Results A total of 187 subjects were included in the primary analysis. In all groups, mean F1 + 2 values were elevated after six months of treatment. Changes were comparable between Treatments 1 and 2 (least squares mean change: 170 pmol/L and 158 pmol/L, respectively) but noticeably larger after Treatment 3 (least squares mean change: 592 pmol/L). The haemostatic effects of Treatment 1 were comparable to those of Treatment 2 and noninferior to those of Treatment 3 (lower limit of 95{\%} confidence interval [- 18.3 pmol/L] > - 130 pmol/L). Conclusions The LNG/EE regimens had similar effects on F1 + 2. Noninferiority was demonstrated between extended regimen LNG/EE and DSG/EE.",
keywords = "Coagulation, Combined oral contraceptives, Desogestrel, Haemostatic, Levonorgestrel",
author = "Nappi, {Rossella E.} and Paoletti, {Anna Maria} and Annibale Volpe and Luca Chiovato and Brandon Howard and Herman Weiss and Nancy Ricciotti",
year = "2014",
doi = "10.3109/13625187.2014.918596",
language = "English",
volume = "19",
pages = "285--294",
journal = "European Journal of Contraception and Reproductive Health Care",
issn = "1362-5187",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Multinational, multicentre, randomised, open-label study evaluating the impact of a 91-day extended regimen combined oral contraceptive, compared with two 28-day traditional combined oral contraceptives, on haemostatic parameters in healthy women

AU - Nappi, Rossella E.

AU - Paoletti, Anna Maria

AU - Volpe, Annibale

AU - Chiovato, Luca

AU - Howard, Brandon

AU - Weiss, Herman

AU - Ricciotti, Nancy

PY - 2014

Y1 - 2014

N2 - Objectives To evaluate the impact of a 91-day extended regimen combined oral contraceptive (150 μg levonorgestrel [LNG]/30 μg ethinylestradiol [EE] for 84 days, followed by 10 μg EE for seven days [Treatment 1]) compared with two traditional 21/7 regimens (21 days 150 μg LNG/30 μg EE [Treatment 2] or 150 μg desogestrel [DSG]/30 μg EE [Treatment 3], both with seven days' hormone free), on several coagulation factors and thrombin formation markers. Methods Randomised, open-label, parallel-group comparative study involving healthy women (18-40 years). The primary endpoint was change from baseline in prothrombin fragment 1 + 2 (F1 + 2) levels over six months. Results A total of 187 subjects were included in the primary analysis. In all groups, mean F1 + 2 values were elevated after six months of treatment. Changes were comparable between Treatments 1 and 2 (least squares mean change: 170 pmol/L and 158 pmol/L, respectively) but noticeably larger after Treatment 3 (least squares mean change: 592 pmol/L). The haemostatic effects of Treatment 1 were comparable to those of Treatment 2 and noninferior to those of Treatment 3 (lower limit of 95% confidence interval [- 18.3 pmol/L] > - 130 pmol/L). Conclusions The LNG/EE regimens had similar effects on F1 + 2. Noninferiority was demonstrated between extended regimen LNG/EE and DSG/EE.

AB - Objectives To evaluate the impact of a 91-day extended regimen combined oral contraceptive (150 μg levonorgestrel [LNG]/30 μg ethinylestradiol [EE] for 84 days, followed by 10 μg EE for seven days [Treatment 1]) compared with two traditional 21/7 regimens (21 days 150 μg LNG/30 μg EE [Treatment 2] or 150 μg desogestrel [DSG]/30 μg EE [Treatment 3], both with seven days' hormone free), on several coagulation factors and thrombin formation markers. Methods Randomised, open-label, parallel-group comparative study involving healthy women (18-40 years). The primary endpoint was change from baseline in prothrombin fragment 1 + 2 (F1 + 2) levels over six months. Results A total of 187 subjects were included in the primary analysis. In all groups, mean F1 + 2 values were elevated after six months of treatment. Changes were comparable between Treatments 1 and 2 (least squares mean change: 170 pmol/L and 158 pmol/L, respectively) but noticeably larger after Treatment 3 (least squares mean change: 592 pmol/L). The haemostatic effects of Treatment 1 were comparable to those of Treatment 2 and noninferior to those of Treatment 3 (lower limit of 95% confidence interval [- 18.3 pmol/L] > - 130 pmol/L). Conclusions The LNG/EE regimens had similar effects on F1 + 2. Noninferiority was demonstrated between extended regimen LNG/EE and DSG/EE.

KW - Coagulation

KW - Combined oral contraceptives

KW - Desogestrel

KW - Haemostatic

KW - Levonorgestrel

UR - http://www.scopus.com/inward/record.url?scp=84904628174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904628174&partnerID=8YFLogxK

U2 - 10.3109/13625187.2014.918596

DO - 10.3109/13625187.2014.918596

M3 - Article

C2 - 24923685

AN - SCOPUS:84904628174

VL - 19

SP - 285

EP - 294

JO - European Journal of Contraception and Reproductive Health Care

JF - European Journal of Contraception and Reproductive Health Care

SN - 1362-5187

IS - 4

ER -